RBC Capital analyst Sabahat Khan maintained a Buy rating on WSP Global (WSP – Research Report) on February 12 and set a price target of ...

Proprietary Insights – Stifel Discover delivers exclusive analysis and commentary from Stifel’s Chief Investment Officer, Chief Economist, Chief Washington Policy Strategist, equity research analysts, ...

Research analysts at Stifel Canada issued their Q4 2024 earnings estimates for shares of Franco-Nevada in a research note ...

Analysts at Stifel Canada reduced their Q4 2024 earnings estimates for shares of IAMGOLD in a research report issued to clients and investors on Tuesday, February 4th. Stifel Canada analyst I. Rico ...

Eagle Financial Services, Inc. (OTCQX: EFSI) (the "Company"), parent company of Bank of Clarke, today announced the pricing ...

United States stocks are at their lowest level since President Donald Trump was sworn in two weeks ago, and other global ...

Good day and welcome to the Stifel Financial fourth quarter financial results conference call. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr ...

(RTTNews) - Stifel Financial Corp. (SF) revealed earnings for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings totaled $234.69 million ...

Inc.; and Stifel Independent Advisors, LLC; in Canada through Stifel Nicolaus Canada Inc.; and in the United Kingdom and Europe through Stifel Nicolaus Europe Limited. The Company’s broker ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...

On Wednesday, Stifel analysts revised their price target for FTAI Aviation (NASDAQ:FTAI) shares, lowering it significantly to $100 from the previous target of $167, while still retaining a Buy ...